Interferon-alpha in the treatment of high-risk haemangiomas in infants

Eur J Pediatr Surg. 2005 Feb;15(1):11-6. doi: 10.1055/s-2004-830550.

Abstract

Background: Haemangiomas are benign tumours that may occasionally compress vital structures, or cause consumptive coagulopathy and heart failure. We describe our recent experience with interferon-alpha as a treatment modality for high-risk haemangiomas.

Patients and methods: Eight children with high-risk haemangiomas were treated with interferon-alpha, six of which had failed previous steroid therapy.

Result: Seven children responded to interferon therapy, one boy with a liver haemangioma died. Mild leucopenia and granulocytopenia were observed in all treated patients. Neurotoxicity occurred in 3 patients and was the most frequent serious complication.

Conclusion: Interferon-alpha is an effective treatment modality for high-risk haemangiomas in children, especially in steroid-resistant patients. The most serious complication was early neurological toxicity.

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • Facial Neoplasms / drug therapy*
  • Female
  • Hemangioma / drug therapy*
  • Humans
  • Infant
  • Interferon-alpha / administration & dosage
  • Interferon-alpha / therapeutic use*
  • Male

Substances

  • Antineoplastic Agents
  • Interferon-alpha